ELISA | Jotup

Longhorn Vaccines and Diagnostics Presents at World Vaccine Congress on Advantages of Single Peptide Vaccine for Broad Coverage of Human and Avian Influenza Viruses

Retrieved on:

Tuesday, April 2, 2024

Results from the poster show that LHNVD-110 generated broadly reactive antibodies to human and highly pathogenic avian influenza viruses while neutralizing seasonal and pandemic influenza strains.

Key Points:

Results from the poster show that LHNVD-110 generated broadly reactive antibodies to human and highly pathogenic avian influenza viruses while neutralizing seasonal and pandemic influenza strains.
This data mirrors previous studies with LHNVD-105, a dual peptide vaccines containing the same epitopes.
Using a single peptide provides a more cost-effective and easily scalable approach to such a universal influenza vaccine.
That is why using peptide-based vaccines with broad strain coverage may offer useful strategies towards preventing influenza, no matter the strain.

Arrayjet’s ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Retrieved on:

Monday, March 18, 2024

Oncology, Health, Medical Devices, Research, Science, Pharmaceutical, Biotechnology, Partnership, 3D bioprinting, Library, Knowledge, Cancer, ELISA, Antibody, Immunome, Mobile phone

Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that its ArrayPlex™ discovery platform has been selected by Immunome, Inc. (NASDAQ: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, to expand its in-house high-throughput screening tools.

Key Points:

Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that its ArrayPlex™ discovery platform has been selected by Immunome, Inc. (NASDAQ: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, to expand its in-house high-throughput screening tools.
ArrayPlex was created by Arrayjet to meet the unique assay requirements of its customers for high-throughput screening services and tools.
During Arrayjet’s successful seven-year partnership with Immunome, Arrayjet performed screening services using the ArrayPlex platform, and the platform underwent further optimisation, most recently to integrate internal assay controls and enhanced data normalisation.
Arrayjet is pleased that Immunome has now chosen to purchase an instrument and internalise the ArrayPlex assay as an in-house, high-throughput screening resource in its efforts to discover targeted cancer therapies.

BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS

Retrieved on:

Monday, April 1, 2024

ISH, Protein Sciences, Education, CiteAb, ELISA, RNA, Antibody, Research, Diagnosis, ACD, Literature, Elisa's

Additionally, Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, was named winner of "The Innovation Award" in recognition of its RNAscope™ ISH technology and its role in helping to advance scientific discovery.

Key Points:

Additionally, Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, was named winner of "The Innovation Award" in recognition of its RNAscope™ ISH technology and its role in helping to advance scientific discovery.
The ELISA Kit Supplier of the Year award is a testament to the depth and breadth of the R&D Systems citation database, which covers reagent data for nearly one million ELISA kit products.
CiteAb's Innovation Award recognizes ACD's RNAscope HiPlex12 Flex Kit, which provides greater flexibility to researchers performing in situ spatial detection of target RNA.
The Innovation Award given to our ACD brand underscores our Spatial Biology team's dedication to enriching our customers' experiences and prioritizing researchers' needs."

Sanyou Bio: Sanyou's Intelligence-Enabled Innovative Biologics R&D Platform Leads in the New Era of Biological Drug Development

Retrieved on:

Wednesday, March 27, 2024

This is the driving force behind Sanyou's development of an intelligence-enabled innovative biologics R&D platform.

Key Points:

This is the driving force behind Sanyou's development of an intelligence-enabled innovative biologics R&D platform.
This system finds extensive applications across various domains, including research and development, data management, project management, quality control, and marketing.
By optimizing drug development processes and supporting intelligence-enabled decision-making, it comprehensively enhances R&D efficiency and accuracy, potentially playing a critical role in drug development.
In drug development, the modeling and prediction of drug developability analysis aims to comprehensively enhance the efficiency of the drug development process.

Physicians Lab Launches the First-of-Its-Kind At-Home Lab Test for Myostatin and Follistatin Levels

Retrieved on:

Wednesday, March 13, 2024

Growth, B cell, Regeneration, Follistatin, Inflammation, Patient, Myostatin, Weight loss, Research, ELISA, Reproduction, TGF, Medicine, Physician, Collection, Blood, Medical imaging

BOCA RATON, Fla., March 13, 2024 /PRNewswire/ -- Physicians Lab, a provider of at-home lab testing for integrative medicine and wellness, launched a new at-home lab test that measures the analytes myostatin and follistatin. The test will show the current myostatin and follistatin levels and the ratio of myostatin to follistatin. The new test will be useful for monitoring muscle loss or growth in individuals.

Key Points:

BOCA RATON, Fla., March 13, 2024 /PRNewswire/ -- Physicians Lab, a provider of at-home lab testing for integrative medicine and wellness, launched a new at-home lab test that measures the analytes myostatin and follistatin.
The test will show the current myostatin and follistatin levels and the ratio of myostatin to follistatin.
Our team is excited to expand Physicians Lab solutions and to offer this at-home lab test to integrative providers and directly to health-conscious consumers."
To determine the values of myostatin and follistatin, Physicians Lab uses a high-sensitivity Enzyme-Linked Immunosorbent Assay (ELISA) technique.

Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference

Retrieved on:

Monday, March 11, 2024

BRISBANE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases and their substrates, a new class of enzymes discovered in-house that are implicated in a broad variety of diseases, today announced an abstract titled “Unveiling of a Novel Therapeutic Antibody Targeting Nitrated Alpha Synuclein for the Treatment of Parkinson’s Disease” was featured in an oral presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference taking place in Lisbon, Portugal from March 5-9, 2024. The presentation outlined data with Nitrase’s first-in-class antibody targeting extracellular nitrated alpha-synuclein (α-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies. Nitrase’s antibody demonstrated both high affinity and selectivity for nitrated synuclein, and it demonstrated the ability to significantly reduce PD progression in in vitro and in vivo PD models.

Key Points:

The presentation outlined data with Nitrase’s first-in-class antibody targeting extracellular nitrated alpha-synuclein (α-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies.
A hallmark of PD pathology is the presence of Lewy Bodies and Lewy Neurites, which have been found to include an accumulation of nitrated α-synuclein.
It has been established in published studies that PD pathology spreads between brain regions along neural circuitry through extracellular aggregated α-synuclein.
Additionally, our antibody demonstrated superiority in a preclinical efficacy evaluation against the parental antibody of prasinezumab, which targets non-nitrated α-synuclein.

Sebia Receives U.S. FDA Clearance for the FLC Kappa & Lambda Assays

Retrieved on:

Thursday, February 29, 2024

Research, Medical Devices, FDA, Other Health, Biotechnology, General Health, Health, Science, Oncology, Other Science, FLC, EIA, Multiple myeloma, Food, ELISA, Willrich, DSM-IV codes, Patient, Diagnosis

Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the FLC Kappa & Lambda assays.

Key Points:

Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the FLC Kappa & Lambda assays.
These are the first EIA tests receiving 510(k) from the FDA for the quantitative detection of both kappa and lambda free light chains in human serum specimens, intended for both aid of diagnosis and monitoring of Multiple Myeloma and Immunoglobulin Light-Chain (AL-) amyloidosis.
Clinical evaluation of Sebia FLC kappa and FLC lambda assay has shown comparable clinical sensitivity with the Freelite assay (96.6% on 177 samples from patients diagnosed with MM) and improved clinical specificity (85.1% on 189 non-myeloma/non-amyloidosis subjects with various clinical conditions).
The ELISA format overcomes main challenges in analytical performance often seen in alternative testing methods” said Arnaud Collin, Sebia Group Vice President Global Regulatory Affairs & Quality.

Applied Biomics Launches Anti-Host Cell Protein (HCP) Antibodies with > 95% Coverage

Retrieved on:

Thursday, February 29, 2024

Biotechnology, Science, Health, Research, HCP, LMW, HMW, WB, C6, ELISA, Proteomics, Antibody, HEK293, CHO, Map, CAP, Fine chemical

Applied Biomics, Inc. , a leading Proteomics service provider, launches a new product line offering Anti-HCP Antibodies with well over 95% coverage.

Key Points:

Applied Biomics, Inc. , a leading Proteomics service provider, launches a new product line offering Anti-HCP Antibodies with well over 95% coverage.
View the full release here: https://www.businesswire.com/news/home/20240228749573/en/
Antibody Coverage of Applied Biomics' Anti-CHO Antibody by 2D Western Blot (WB).
Following are highlights of Applied Biomics’ HCP Antibodies:
High HCP coverage: Detects well over 2500 (up to ~5000) low and high molecular weight (LMW & HMW) HCPs, with > 95% overall HCP coverage and > 90% each quadrant coverage.
With our leading HCP antibody coverage services , customers can now test Applied Biomics’ HCP antibody against their process specific HCPs, or compare with other HCP antibodies to find a better fit.

Lab Automation Markets: Liquid Handling, Nucleic Acid Purification System, Microplate Reader, ELISA, Storage & Retrieval, LIMS, ELN Software - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on:

Tuesday, February 27, 2024

The "Lab Automation Market by Product (Liquid Handling, Nucleic Acid Purification System, Microplate Reader, ELISA, Storage & Retrieval, LIMS, ELN Software), Application (Drug Discovery, Diagnostics, Genomics & Proteomics), End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Lab Automation Market by Product (Liquid Handling, Nucleic Acid Purification System, Microplate Reader, ELISA, Storage & Retrieval, LIMS, ELN Software), Application (Drug Discovery, Diagnostics, Genomics & Proteomics), End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
The global lab automation market is projected to reach $10.54 billion by 2030, at a CAGR of 7.2% from 2023 to 2030.
Among products, in 2023, the systems segment is expected to account for the largest share of the lab automation market.
Among applications, in 2023, the drug discovery segment is expected to account for the largest share of the lab automation market.

TECHNOCLONE RECEIVES US FDA MARKETING AUTHORIZATION FOR THE FIRST ADAMTS13 ACTIVITY DIAGNOSTIC TEST

Retrieved on:

Tuesday, March 5, 2024

Doctor of Philosophy, MD, FDA, Food, De novo, ELISA, Thrombotic microangiopathy, TTP, Patient, TMA, CSO, Plasma, Diagnosis, Thrombotic thrombocytopenic purpura, Laboratory, ADAMTS13

WEST CHESTER, Ohio, March 5, 2024 /PRNewswire/ -- Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, world-leading producer of diagnostic tests, equipment, and research products in the field of blood clotting and its exclusive distributor in the USA, DiaPharma Group, Inc., are pleased to announce that the US Food and Drug Administration (FDA) granted De Novo marketing authorization for Technozym ADAMTS13 Activity ELISA.

Key Points:

WEST CHESTER, Ohio, March 5, 2024 /PRNewswire/ -- Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, world-leading producer of diagnostic tests, equipment, and research products in the field of blood clotting and its exclusive distributor in the USA, DiaPharma Group, Inc., are pleased to announce that the US Food and Drug Administration (FDA) granted De Novo marketing authorization for Technozym ADAMTS13 Activity ELISA.
This is the first ADAMTS13 activity test authorized by the FDA.
The Technozym ADAMTS13 Activity assay is an enzyme-linked immunosorbent assay (ELISA) intended for the qualitative determination of ADAMTS13 activity in platelet poor human citrated plasma.
"In line with our commitment to provide ADAMTS13 diagnostics globally, we are excited about this milestone, having the first ADAMTS13 activity test granted with marketing authorization by the FDA", says Nikolaus Binder, MD, PhD, CSO of Technoclone.